191 related articles for article (PubMed ID: 9884334)
1. Targeting of functional antibody-CD59 fusion proteins to a cell surface.
Zhang HF; Yu J; Bajwa E; Morrison SL; Tomlinson S
J Clin Invest; 1999 Jan; 103(1):55-61. PubMed ID: 9884334
[TBL] [Abstract][Full Text] [Related]
2. Targeting of functional antibody-decay-accelerating factor fusion proteins to a cell surface.
Zhang H; Lu S; Morrison SL; Tomlinson S
J Biol Chem; 2001 Jul; 276(29):27290-5. PubMed ID: 11352906
[TBL] [Abstract][Full Text] [Related]
3. The complement regulatory protein CD59: insights into attenuation of choroidal neovascularization.
Schnabolk G; Tomlinson S; Rohrer B
Adv Exp Med Biol; 2014; 801():435-40. PubMed ID: 24664728
[TBL] [Abstract][Full Text] [Related]
4. Identification of mutations in rat CD59 that increase the complement regulatory activity.
Hinchliffe SJ; Morgan BP
Biochemistry; 2000 May; 39(19):5831-7. PubMed ID: 10801333
[TBL] [Abstract][Full Text] [Related]
5. Longitudinally extensive NMO spinal cord pathology produced by passive transfer of NMO-IgG in mice lacking complement inhibitor CD59.
Zhang H; Verkman AS
J Autoimmun; 2014 Sep; 53():67-77. PubMed ID: 24698947
[TBL] [Abstract][Full Text] [Related]
6. Activity after site-directed mutagenesis of CD59 on complement-mediated cytolysis.
Zhu X; Gao M; Ren S; Wang Q; Lin C
Cell Mol Immunol; 2008 Apr; 5(2):141-6. PubMed ID: 18445344
[TBL] [Abstract][Full Text] [Related]
7. Serum-resistant strains of Borrelia burgdorferi evade complement-mediated killing by expressing a CD59-like complement inhibitory molecule.
Pausa M; Pellis V; Cinco M; Giulianini PG; Presani G; Perticarari S; Murgia R; Tedesco F
J Immunol; 2003 Mar; 170(6):3214-22. PubMed ID: 12626580
[TBL] [Abstract][Full Text] [Related]
8. Effect of C2-associated carbohydrate structure on Ig effector function: studies with chimeric mouse-human IgG1 antibodies in glycosylation mutants of Chinese hamster ovary cells.
Wright A; Morrison SL
J Immunol; 1998 Apr; 160(7):3393-402. PubMed ID: 9531299
[TBL] [Abstract][Full Text] [Related]
9. CD59 blocks not only the insertion of C9 into MAC but inhibits ion channel formation by homologous C5b-8 as well as C5b-9.
Farkas I; Baranyi L; Ishikawa Y; Okada N; Bohata C; Budai D; Fukuda A; Imai M; Okada H
J Physiol; 2002 Mar; 539(Pt 2):537-45. PubMed ID: 11882685
[TBL] [Abstract][Full Text] [Related]
10. Amplified gene expression in CD59-transfected Chinese hamster ovary cells confers protection against the membrane attack complex of human complement.
Zhao J; Rollins SA; Maher SE; Bothwell AL; Sims PJ
J Biol Chem; 1991 Jul; 266(20):13418-22. PubMed ID: 1712784
[TBL] [Abstract][Full Text] [Related]
11. A novel bifunctional chimeric complement inhibitor that regulates C3 convertase and formation of the membrane attack complex.
Fodor WL; Rollins SA; Guilmette ER; Setter E; Squinto SP
J Immunol; 1995 Nov; 155(9):4135-8. PubMed ID: 7594566
[TBL] [Abstract][Full Text] [Related]
12. Characteristics of CD59 up-regulation induced in porcine endothelial cells by alphaGal ligation and its association with protection from complement.
Grubbs BC; Benson BA; Dalmasso AP
Xenotransplantation; 2003 Sep; 10(5):387-97. PubMed ID: 12950982
[TBL] [Abstract][Full Text] [Related]
13. Identification and functional characterization of a new gene encoding the mouse terminal complement inhibitor CD59.
Qian YM; Qin X; Miwa T; Sun X; Halperin JA; Song WC
J Immunol; 2000 Sep; 165(5):2528-34. PubMed ID: 10946279
[TBL] [Abstract][Full Text] [Related]
14. Human CD59 inhibitor sensitizes rituximab-resistant lymphoma cells to complement-mediated cytolysis.
Hu W; Ge X; You T; Xu T; Zhang J; Wu G; Peng Z; Chorev M; Aktas BH; Halperin JA; Brown JR; Qin X
Cancer Res; 2011 Mar; 71(6):2298-307. PubMed ID: 21252115
[TBL] [Abstract][Full Text] [Related]
15. Cytokine-mediated up-regulation of CD55 and CD59 protects human hepatoma cells from complement attack.
Spiller OB; Criado-García O; Rodríguez De Córdoba S; Morgan BP
Clin Exp Immunol; 2000 Aug; 121(2):234-41. PubMed ID: 10931136
[TBL] [Abstract][Full Text] [Related]
16. Insights into the human CD59 complement binding interface toward engineering new therapeutics.
Huang Y; Smith CA; Song H; Morgan BP; Abagyan R; Tomlinson S
J Biol Chem; 2005 Oct; 280(40):34073-9. PubMed ID: 16079145
[TBL] [Abstract][Full Text] [Related]
17. Structure/function characterization of porcine CD59: expression, chromosomal mapping, complement-inhibition, and costimulatory activity.
Maher SE; Pflugh DL; Larsen NJ; Rothschild MF; Bothwell AL
Transplantation; 1998 Oct; 66(8):1094-100. PubMed ID: 9808497
[TBL] [Abstract][Full Text] [Related]
18. Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma.
Weng WK; Levy R
Blood; 2001 Sep; 98(5):1352-7. PubMed ID: 11520782
[TBL] [Abstract][Full Text] [Related]
19. Mapping the active site of CD59.
Yu J; Abagyan R; Dong S; Gilbert A; Nussenzweig V; Tomlinson S
J Exp Med; 1997 Feb; 185(4):745-53. PubMed ID: 9034152
[TBL] [Abstract][Full Text] [Related]
20. Mutational analysis of the active site and antibody epitopes of the complement-inhibitory glycoprotein, CD59.
Bodian DL; Davis SJ; Morgan BP; Rushmere NK
J Exp Med; 1997 Feb; 185(3):507-16. PubMed ID: 9053451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
